Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2021-09-28 Director's Dealing
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-09-28 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-14 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-14 English
424B7
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(7) under the Securities Act of 1933. It details the registration and offering of common stock shares by a selling stockholder, including terms of the offering, risk factors, use of proceeds, and plan of distribution. This type of document is related to capital raising activities and financing disclosures rather than financial performance reports, management changes, or regulatory certifications. It is not an annual or quarterly report, earnings release, or management discussion. The presence of registration fee calculations and offering details confirms it is a capital/financing update filing.
2021-08-25 English
424B7
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(7) under the Securities Act of 1933. It details the registration and offering of common stock by a selling stockholder, including the number of shares, pricing, and plan of distribution. The document includes legal disclaimers, risk factors, and company overview but does not contain financial statements or management discussion of financial results. It is a disclosure related to a securities offering, specifically a resale of shares by a selling stockholder, which fits the definition of a Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes. The document is not an annual or quarterly report, earnings release, or other financial report type. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-08-12 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes a base prospectus and sales agreement prospectus for offerings of common stock, preferred stock, debt securities, warrants, and units. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or notice, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2021-08-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.